Icosapent ethyl for CV risk reduction: who and when?
Details & Video
Program details and agenda: Select TABS on the left (computer) or SCROLL DOWN (phone)
View the Links & Resources tab to download the program slides and a transcript, as well as review the list of other podcast platforms where you can listen to this program.
Overview & Objectives
Icosapent ethyl, as shown in the REDUCE-IT study, represents the first agent to improve CV outcomes when added to statin therapy in high-risk patients with elevated triglyceride levels. The clinical benefits of icosapent ethyl are impressive, with demonstrated safety and tolerability, thus creating a major opportunity for the prevention of CV events and mortality in Canada.
However, there are substantial complexities for clinicians to adopt icosapent ethyl in the management of high risk patients. This podcast discusses the use of Icosapent ethyl for CV risk reduction with a focus on which patient and when this treatment should be considered.
|Do serum triglycerides predict risk?||Milan Gupta|
|Do fish oils reduce risk?||Shaun Goodman|
|What are the key results from REDUCE-IT?||Milan Gupta|
|In which patients should we consider icosapent ethyl?||All|
|Do serum triglycerides predict risk?|
|Do fish oils reduce risk?|
|What are the key results from REDUCE-IT?|
|In which patients should we consider icosapent ethyl?|
Canadian Collaborative Research Network